This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Top Takes From RealMoney

The RealMoney contributors are in the business of trading and investing all day on the basis of ongoing news flow. Below, we offer the top five ideas that RealMoney contributors posted today and how they played those ideas.

TheStreet.com brings you the news all day, and with RealMoney's "Columnist Conversation," you can see how the pros are playing it on a real-time basis. Here are the top five ideas played today. To see all that RealMoney offers, click here for a free trial.

1. AMAG: FDA decision on Feraheme in a Few Days
By Adam Feuerstein
6:28 a.m. EDT



AMAG Pharmaceuticals (AMAG - Get Report) expects the FDA to announce an approval decision on its IV iron replacement product Feraheme "within the next few days," the company said Monday night, based on contact from the regulatory agency. The FDA's decision was supposed to come Monday.

The FDA has not requested any additional information from AMAG and no outstanding issues remain regarding Feraheme, according to the company.

So, what does this all mean for AMAG? Two possible scenarios: First, this latest delay is simply an administrative backlog at the FDA. It is taking longer than expected to get all the signatures and sign-offs necessary for Feraheme's full approval, so this latest, short delay is no big deal.

Second, the FDA does have a significant (and unidentified) problem with Feraheme's approval so the drug is now in regulatory limbo. A delay could stretch on for months, as has happened with Cardiome's (CRME - Get Report) drug for atrial fibrillation.

I fear the second scenario, of course, but I doubt it. An administrative holdup at the FDA is the more likely reason for this delay, so I wouldn't panic. Longtime followers of AMAG have already built up their calluses over the past six months or so; a few more days is not too long to wait.

AMAG is holding a conference call at 8:30 a.m. EDT.

No positions.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AMAG $55.04 0.51%
CRME $8.61 -0.92%
AAPL $132.73 0.06%
FB $81.36 -0.67%
GOOG $554.27 -0.20%

Markets

DOW 18,106.10 +68.13 0.38%
S&P 500 2,113.27 +4.35 0.21%
NASDAQ 5,068.2760 +8.03 0.16%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs